天康生物(002100.SZ)半年度淨利潤預降68.82%-73.61%
格隆匯7月14日丨天康生物(002100.SZ)公佈,預計2021年半年度歸屬於上公司股東的淨利潤2.2億元-2.6億元,同比下降68.82%-73.61%;扣除非經常性損益後的淨利潤2.3億元-2.7億元,同比下降68.47%-73.14%。
報吿期內,受市場行情影響,生豬銷售價格從年初持續回落,使得公司生豬養殖業務盈利同比有較大下降;飼料業務加速產業一體化建設,銷量及利潤實現較好增長;生物疫苗隨着市場苗拓展銷量明顯增長,業務產品盈利能力提升,銷量及利潤均較上年實現增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.